FB102 — Topline data
H2 2026
A Phase 1b alopecia areata trial is ongoing with data expected in the second half of 2026.Source filing
ARGX biotech catalysts & pipeline
ARGENX SE · Data as of 2026-09-08
Upcoming catalysts
ARGX-124 — Full data
Late 2026
ARGX-124 expected to complete Phase 1 by end of 2026Source filing
VYVGART (efgartigimod alfa-fcab) — Regulatory decision
Late 2026
VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026Source filing
VYVGART IV — Regulatory decision
Late 2026
Submitted supplemental Biologics License Application (sBLA) for VYVGART IV for anti-acetylcholine receptor antibody negative gMG (MuSK+, LRP4+ and triple seronegative); if approved, launch expected by end of 2026Source filing
empasiprubart — Topline data
Q4 2026
Topline results from registrational EMPASSION study (MMN) expected in fourth quarter of 2026Source filing
VYVGART (efgartigimod alfa-fcab) — Topline data
H1 2027
Topline results from registrational ADVANCE-NEXT study (primary ITP) expected in first half of 2027Source filing
empasiprubart — Topline data
H2 2027
Topline results from registrational EMVIGORATE and EMNERGIZE studies (CIDP) expected in second half of 2027Source filing
VYVGART (efgartigimod alfa-fcab) — Topline data
H2 2027
Topline results from registrational UNITY study (Sjogren's disease) expected in second half of 2027Source filing